Aggressive histiocytic lesions are uncommon in the pediatric population. These neoplasms occur in isolation or after therapy for other types of hematopoietic malignancy such as T-cell acute lymphoblastic leukemia. The etiology of these lesions is poorly understood, and no definitive standard of care has been established for patients with these diagnoses. Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation—metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma—in pediatric patients. Our findings highlight the importance of considering thalidomide therapy in this unique and difficult to treat patient population.
Departments of *Pediatrics and Communicable Diseases, University of Michigan Medical School
§Radiology, Division of Nuclear Medicine, University Hospital
†Pathology, University of Michigan, Ann Arbor, MI
‡Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
L.M.M.L. is supported by the Shirley K. Schlafer Foundation.
The authors declare no conflict of interest.
Reprints: Linda McAllister-Lucas, MD, PhD, University of Michigan Medical Center, 3520 MSRB1, 1150 West Medical Center Drive, Ann Arbor, MI 48109 (e-mail: firstname.lastname@example.org).
Received January 12, 2012
Accepted March 29, 2012